Calibrium

Discovering and developing novel peptides for diabetes and related metabolic diseases

Calibrium is focused on new approaches to treat diabetes and related metabolic disorders. The Calibrium leadership team (including co-founders Richard DiMarchi and Fritz French) was previously affiliated with Marcadia Biotech, which was also focused on novel diabetes therapeutics and sold to Roche in 2010.

Status

Acquired by Novo Nordisk in 2015

Year of Investment

2013

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Carmel, Indiana

Frazier Team

Website